BMY
NYSE · Pharmaceuticals
Bristol-Myers Squibb Co
$64.72
+0.57 (+0.89%)
BMY News30 articles
Pfizer Stock Rises as Core Drug Growth Offsets COVID Decline
Pfizer (PFE) shares rose 0.9% after Q2 results beat estimates, with non-COVID drug growth offsetting a steep decline in COVID product sales.
Geron Stock Jumps 18% as Rytelo Sales Align with Guidance
Geron (GERN) shares jumped 18% as Q2 Rytelo sales of $57.5M edged closer to guidance midpoint, with management raising revenue expectations.
Dow Rises on Rate-Sensitive Gains While Market Breadth Weakens
The Dow gained 0.87% even as private payrolls missed forecasts and ISM prices jumped. Nasdaq and small caps declined, with weak breadth and healthcare outperforming tech.
Pfizer Stock Rises as Non-COVID Drugs Offset Pandemic Revenue Slump
Pfizer's Q2 beat estimates as four growth brands offset COVID revenue declines. Shares rose 1.48% premarket.
Bristol Myers Soars on AstraZeneca Takeover Talks, But Market Cap Math Raises Red Flags
Bristol Myers Squibb (BMY) surged 8% on AstraZeneca (AZN) merger speculation, but combined market cap fell $6.2B. Strong Q2 results and raised guidance bolster standalone case.
AstraZeneca slides on Bristol Myers tie-up talks; $5B value gap emerges
AstraZeneca shares dropped 5% on report of early merger talks with Bristol Myers Squibb, which gained 6% premarket. Combined market value fell about $5.2 billion.
FDA Panel Nod Sparks $763M Value Shift Between Melanoma Drugmakers
Replimune (REPL) soared 107% after an FDA panel endorsed RP1, while Iovance (IOVA) tumbled 13%, shifting $763 million in market value between the two melanoma therapy rivals.
Bristol Myers Squibb at Crossroads as AstraZeneca Merger Talks Surface
Bristol Myers Squibb shares rose 5.2% last week after strong Q2 earnings, but a reported $400B merger approach from AstraZeneca puts the stock in focus Monday.
AZN-BMY Merger Talks: A $455B Pharma Mega-Deal in the Making?
AstraZeneca and Bristol Myers Squibb are reportedly in merger talks, which could create a $455 billion pharmaceutical giant. Reuters has not confirmed the report.
Replimune Surges 107% as FDA Panel Backs RP1 Despite Data Discrepancies
Replimune shares soared 107% after an FDA panel endorsed RP1's efficacy data, despite conflicting response rates. The FDA decision is expected by August 2.
Pfizer Stock Climbs Ahead of Q2 Earnings on Strong Eliquis Sales Signal
Pfizer shares gained 2% this week ahead of Q2 earnings, bolstered by partner Bristol Myers' strong Eliquis sales and raised 2026 outlook.
Replimune Rockets 131% on FDA Panel Backing for RP1
Replimune shares jumped 131% to $12.50 after an FDA panel voted 10-3 that RP1's efficacy data is interpretable and clinically important, adding nearly $600 million in market value.
Pfizer Stock Dips 1.9% but Dividend Adjusts Decline
Pfizer ended Friday at $24.54, down 1.9% unadjusted, but dividend-adjusted returns fell just 0.16%. The FDA's priority review for Talzenna offers a key catalyst for Q4.
Nvidia Shares Slip as Focus Shifts to Customer Profitability
Nvidia shares fell 0.74% in premarket as investors shift focus to customer profitability despite a $700M US plant and $60B in server orders.
Nvidia Edges Up on $4B Nebius Stake Disclosure
Nvidia shares gained 1.1% premarket after an SEC filing disclosed a $4.06 billion beneficial ownership stake in Nebius Group, primarily through warrants.
Pfizer Gains 3.6% as Dividend Yield Attracts Income Investors
Pfizer (PFE) shares climbed 3.6% as its 6.9% dividend yield attracted income-focused investors, despite unchanged analyst estimates and a slight earnings forecast cut.
Agenus Shares Surge 83% on $340M Financing for Key Colon Cancer Trial
Agenus shares surged 83% on news of up to $340M financing for a pivotal colon cancer trial, but three-quarters of that amount hinges on investor warrants.
Agenus Stock Surges 59% on $340 Million Funding Deal
Agenus (AGEN) shares jumped 59% premarket on a $340 million financing deal, though full exercise of warrants could nearly triple the share count. The funds support a strategic pivot to a major colon cancer trial.
Pfizer's 7% Yield Attracts Income Seekers as Pharma Sector Stalls
Pfizer shares edged up 1.84% to $24.32, offering a 7.07% yield, but the stock has declined 14.12% over the past three months amid a sluggish pharmaceutical sector.
Pfizer Gains as 7% Yield Attracts, China Trial Scrutiny Looms
Pfizer (PFE) shares climbed 2.1% on Thursday, supported by a high dividend yield, but a U.S. House committee probe into its China trial data adds uncertainty.
Amazon Ousts Walmart to Top Fortune 500, Reshaping Corporate Peeking Order
Amazon has claimed the top spot on the 2026 Fortune 500, ending Walmart's 13-year run and signaling a shift in corporate power driven by e-commerce, cloud computing, and healthcare.
Amazon Ousts Walmart as Fortune 500 Leader; Regional Giants Shine
Amazon unseats Walmart as Fortune 500 No. 1, breaking a 13-year streak. Erie Insurance rises, New Jersey boasts 15 firms, and New England has over 20 companies on the list.
Merck Shares Jump as New Drug Data Eases Keytruda Concerns
Merck shares surged 4.9% to $120.26 after ASCO data showed its new cancer drug sac-TMT combined with Keytruda improved progression-free survival, reinforcing confidence in the post-Keytruda pipeline.
Pfizer's Cancer Pipeline Takes Center Stage After ASCO Data Dump
Pfizer enters Monday's trading with a wealth of new cancer drug data from ASCO and a $10.5B China partnership, positioning the stock for a potential re-rating.
Replimune Surges 85% on FDA Priority Review for Melanoma Drug
Replimune shares soared 85% after the FDA agreed to a priority review for its melanoma drug RP1, following a previous rejection. New trial data is expected soon.
Regeneron Plunges 10% on Melanoma Drug Trial Failure
Regeneron Pharmaceuticals shares dropped 9.8% Monday after its late-stage melanoma drug trial with fianlimab failed to meet its primary endpoint, missing statistical significance versus Merck's Keytruda.
Wall Street Slips as Tech Retreats, Bond Yields Stay Elevated
U.S. stocks declined Monday as technology shares lost momentum ahead of Nvidia's earnings, while rising oil and elevated bond yields kept inflation concerns in focus.
Regeneron Shares Slide After Melanoma Combo Misses Key Goal
Regeneron shares tumbled 11.8% in premarket trading after its melanoma drug combo missed statistical significance on progression-free survival versus Keytruda.
Pfizer Faces Investor Scrutiny After Weekly Decline Amid Pipeline Concerns
Pfizer shares dropped 1.63% on Friday to $25.33, lagging the S&P 500. Despite a 5% revenue increase and reaffirmed 2026 guidance, investor caution persists over pipeline risks and competitive pressure from Eli Lilly.
Pfizer Q1 Beats Estimates, Patent Cliff Concerns Linger
Pfizer reported Q1 adjusted EPS of $0.75 on $14.45B revenue, beating estimates. Growth in Eliquis and Padcev offset COVID declines, but patent cliff remains a key concern.